Case Reports in Oncology最新文献

{"title":"Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients.","authors":"William Makis, Ilyes Baghli, Pierrick Martinez","doi":"10.1159/000546362","DOIUrl":"10.1159/000546362","url":null,"abstract":"<p><strong>Background: </strong>Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited.</p><p><strong>Case presentations: </strong>This report highlights 3 cases of patients with advanced cancer - including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after incorporating FBZ into their treatment regimens alongside other therapies (excluding chemotherapy). All three patients tolerated FBZ without any reported adverse effects, and remission was sustained during follow-up periods ranging from 11 months to nearly 3 years.</p><p><strong>Conclusion: </strong>FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology. Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"856-863"},"PeriodicalIF":0.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive Bone Marrow Involvement by <i>BRAF</i> ^V660E-Mutated Bi-Phenotypic Erdheim-Chester Neoplasm/Rosai-Dorfman Disease (Mixed Histiocytic Neoplasm) with Atypical Histological Features and Fulminant Hemophagocytosis.","authors":"Dina Soliman, Firyal Ibrahim, Hasan Rizvi, Mahir Petkar, Zsolt Lengyel, Aliya Habib Sange, Awni Alshurafa, Ruba Yasin","doi":"10.1159/000545775","DOIUrl":"10.1159/000545775","url":null,"abstract":"<p><strong>Background: </strong>Erdheim-Chester disease (ECD) is a recently recognized clonal hematopoietic neoplasm characterized by activating alterations in the MAPK pathway. It involves multi-organ accumulation of abnormal histiocytes, leading to nonspecific clinical manifestations due to inflammation and fibrosis caused by histiocytic infiltration.</p><p><strong>Case presentation: </strong>We present a 45-year-old male with nonspecific clinical symptoms and progressive skin and abdominal lesions. Multiple tissue biopsies revealed fibrohistiocytic infiltration but provided an inconclusive diagnosis. Imaging studies showed extensive fibrosis in the perinephric regions on CT and sclerotic foci in long and pelvic bones on PET/CT. Bone marrow biopsy revealed abnormal histiocytes with multinucleated giant forms, prominent emperipolesis, active hemophagocytosis, and condensed hemosiderin deposition. Immunohistochemistry showed positive histiocytes for CD68, CD163, and partially for S-100. Molecular analysis confirmed the <i>BRAFV660E</i> mutation, establishing a diagnosis of ECD with atypical histologic features and findings overlapping with Rosai-Dorfman (mixed histiocytosis). The diagnosis was challenging due to extensive fibrosis, the lack of typical histopathologic features of ECD, in addition to concurrent involvement by Rosai-Dorfman cells (mixed histiocytosis), activated macrophages, and dense hemosiderin deposition - a morphologic characteristic not previously described in ECD. Unfortunately, the diagnosis was delayed by 6 years, which tragically led to a fatal outcome.</p><p><strong>Conclusion: </strong>The case highlights the need to recognize that ECD diagnosis requires integrating histopathology with clinical and radiographic findings. It emphasizes the importance of awareness of mixed histiocytosis features and the role of detecting BRAF mutations, even through immunohistochemistry, in suspected histiocytic neoplasms. Extensive bone marrow involvement by ECD is rarely described. To our knowledge, there are no prior reports of bi-phenotypic (concurrent) ECD/RDD mixed histiocytosis affecting the bone marrow.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"602-612"},"PeriodicalIF":0.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical Lymphadenopathy in Concomitant CML and Tuberculosis: A Case Report.","authors":"Afia Aziz, Awni Alshurafa, Mohammad Yassin","doi":"10.1159/000546368","DOIUrl":"10.1159/000546368","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic myeloid leukemia is a myeloproliferative disorder characterized by the uncontrolled proliferation of mature and maturing granulocytes in the bone marrow, along with the presence of the Philadelphia chromosome. Lymphadenopathy is an uncommon initial manifestation of CML and is typically attributed to the disease itself. However, with the use of tyrosine kinase inhibitors (TKIs), which can affect T-cell-mediated immunity, new or persistent lymphadenopathy in CML patients warrants investigation to rule out opportunistic infections, including tuberculosis (TB), or progression to the blast phase of CML.</p><p><strong>Case presentation: </strong>A 35-year-old male diagnosed with chronic-phase CML initially presented with cervical lymphadenopathy. The lymphadenopathy was initially attributed to CML. Further evaluation, including a lymph node biopsy, revealed concurrent TB infection. Treatment with appropriate anti-tuberculous therapy led to the resolution of the lymphadenopathy.</p><p><strong>Conclusion: </strong>This case highlights the importance of considering opportunistic infections, such as TB, in CML patients presenting with lymphadenopathy, particularly those on TKI therapy. Prompt investigation and appropriate management are crucial to avoid complications and ensure optimal patient outcomes.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"751-755"},"PeriodicalIF":0.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12173442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inadequate Ovarian Function Suppression with GnRH Agonists and Subsequent Bilateral Salpingo-Oophorectomy Revealing Ovarian Stromal Hyperplasia in a Premenopausal Woman with Early-Stage, Hormone Receptor-Positive Breast Cancer: A Case Report.","authors":"Leyla Bayat, Kelsey Kossl, Amanda Pechman, Alan Marcus, Maryann Kwa","doi":"10.1159/000546479","DOIUrl":"10.1159/000546479","url":null,"abstract":"<p><strong>Background: </strong>A current standard treatment for pre- or perimenopausal women with high-risk early-stage, hormone receptor-positive breast cancer who have undergone definitive surgery is adjuvant treatment with ovarian function suppression (OFS) with a GnRH agonist (leuprolide or goserelin) with endocrine therapy with an aromatase inhibitor or tamoxifen. Routine measurement of serum estradiol levels for monitoring of OFS during treatment is not a part of current NCCN guidelines. The frequency of estradiol monitoring is therefore often at the discretion of the clinician, and the goal estradiol level is not well established.</p><p><strong>Case presentation: </strong>We present the case of a 47-year-old female with high-risk early-stage hormone receptor-positive breast cancer who despite use of GnRH agonists did not achieve an estradiol level within the postmenopausal range. She had received two different GnRH agonists (leuprolide and goserelin) and later underwent a bilateral salpingo-oophorectomy (BSO). The pathology showed stromal hyperplasia in both ovaries. After the BSO in April 2024, the GnRH agonist was stopped. The serum estradiol level remained elevated (not in the postmenopausal range) after surgery for 12 months, prior to decreasing to the postmenopausal range.</p><p><strong>Conclusion: </strong>Our patient's clinical course highlights the need for better understanding and establishment of monitoring guidelines for estradiol and the optimal degree of ovarian suppression for patients with breast cancer receiving OFS.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"864-871"},"PeriodicalIF":0.7,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Entrectinib-Induced Pericarditis with Cardiac Tamponade in a Patient with Neurotrophic Tropomyosin Receptor Kinase 1 Fusion-Positive Breast Cancer.","authors":"Aki Aoyama, Yutaro Yoshitomi, Akihiko Shimomura, Yukino Kawamura, Tomoko Taniyama, Atsumasa Kurozumi, Shuji Kubota, Yukio Hiroi, Chikako Shimizu","doi":"10.1159/000546503","DOIUrl":"10.1159/000546503","url":null,"abstract":"<p><strong>Introduction: </strong>Entrectinib is a multikinase inhibitor used to treat neurotrophic tropomyosin receptor kinase (<i>NTRK</i>) fusion-positive, locally advanced, or metastatic tumors. Cardiovascular events, such as congestive heart failure and myocarditis, have been reported in association with entrectinib use.</p><p><strong>Case presentation: </strong>A 31-year-old female with <i>NTRK1</i> fusion-positive breast cancer presented to our hospital with dyspnea and orthopnea 21 days after initiating entrectinib therapy (600 mg/day orally). Transthoracic echocardiography revealed circumferential pericardial effusion with diastolic right atrial and ventricular collapse. Consequently, she was diagnosed with pericarditis complicated by cardiac tamponade, and pericardiocentesis was performed. Cardiac tamponade resolved after discontinuation of entrectinib and initiation of corticosteroid therapy. Subsequently, larotrectinib (200 mg/day orally) was initiated.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first reported case of entrectinib-induced pericarditis complicated by cardiac tamponade. Patients should be closely monitored for signs of pericarditis and cardiac tamponade at the start of entrectinib therapy. In patients who develop cardiovascular toxicity due to entrectinib, larotrectinib may be considered as an alternative treatment.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"824-829"},"PeriodicalIF":0.7,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Century of Hypomethylating Agent: A Remarkable Response to Azacitidine Monotherapy for Relapsed Acute Myeloid Leukemia - A Case Report.","authors":"Chetan Jeurkar, Amry Majeed, Lindsay Wilde, Gina Keiffer, Margaret Kasner","doi":"10.1159/000545569","DOIUrl":"https://doi.org/10.1159/000545569","url":null,"abstract":"<p><strong>Introduction: </strong>Acute myeloid leukemia (AML) is a disease of the elderly with a median age at diagnosis of 68 and with a very poor prognosis outside of those patients who have cytogenetic and/or molecular findings which confer a better prognosis. Most fit patients are treated with chemotherapy and then allogeneic hematopoietic stem cell transplant if they are intermediate or poor risk by ELN 2022 criteria (aSCT). aSCT is the mainstay of curative treatment although many patients are not candidates due to age, performance status, and comorbidities. In patients who are not candidates for curative treatment, low-intensity chemotherapy regimens, including monotherapy with hypomethylating agents (HMAs) such as azacitidine or decitabine, may be trialed with a palliative intent. In patients who have relapsed disease, responses to therapy are generally dismal and overall survival is extremely low.</p><p><strong>Case presentation: </strong>We report a 73-year-old male patient who was initially diagnosed with inversion 16 AML, underwent induction chemotherapy with 7 + 3 and then consolidation with 4 cycles of high-dose cytarabine. He was found to have relapse after consolidation but did not elect to undergo allogeneic bone marrow transplant and so was given palliative single-agent azacitidine. He has since received over 100 cycles of azacitidine and remains in remission.</p><p><strong>Conclusion: </strong>To our knowledge, no other reports describe relapsed AML treated with HMA monotherapy achieving such exceptional survival. The remarkable response duration suggests mechanisms beyond cytotoxicity. Further research should explore HMA monotherapy's effects across AML subgroups, including inv(16).</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"575-581"},"PeriodicalIF":0.7,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consecutive Uncontrolled Gastrointestinal Immune-Related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma: A Case Report.","authors":"Yoshikazu Toshima, Keiki Yokoo, Koki Kamata, Takayuki Nagao, Satoshi Ota, Gen Yamada, Hirofumi Chiba","doi":"10.1159/000546295","DOIUrl":"10.1159/000546295","url":null,"abstract":"<p><strong>Introduction: </strong>Immune-checkpoint inhibitors, such as pembrolizumab, have been used for non-small cell lung cancer treatment but are often associated with immune-related adverse events (irAEs).</p><p><strong>Case presentation: </strong>A 71-year-old female was diagnosed with lung adenocarcinoma (cT3N0M1c; BRN, cStage IVB [UICC-8th edition]) and was treated with pembrolizumab monotherapy, achieving a partial response. After five cycles, she developed anorexia and abdominal pain, and upper gastrointestinal endoscopy revealed hemorrhagic gastritis because of irAEs. Systemic steroids improved the gastritis, and pembrolizumab was re-administered. However, after re-treatment, she developed interstitial lung disease, enteritis, and recurrent gastritis, all of which were irAEs. Despite high-dose steroids and infliximab addition, the irAEs remained uncontrolled, and the patient eventually died.</p><p><strong>Conclusion: </strong>Caution is essential when re-administering immune-checkpoint inhibitors to patients with prior irAEs, although upper gastrointestinal irAEs are usually manageable.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"794-799"},"PeriodicalIF":0.7,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Mediastinal Large B-cell Lymphoma: A Diagnostic Conundrum.","authors":"Yazan Alrefai, Shruti Wadhwani, Nikita Wadhwani, Ayrton Bangolo, Jason Mizrahi, Tatyana Feldman","doi":"10.1159/000545931","DOIUrl":"10.1159/000545931","url":null,"abstract":"<p><strong>Introduction: </strong>Primary mediastinal large B-cell lymphoma (PMBCL) is a rare and aggressive non-Hodgkin lymphoma originating from mediastinal thymic B cells. Its peculiar molecular signature assists in differentiating it from other subtypes of non-Hodgkin lymphoma.</p><p><strong>Case report: </strong>We present a rare case of PMBCL in a 39-year-old male with a bulky mediastinal mass that resulted in superior vena cava thrombosis and cardiac tamponade. Diagnostic discordance between histopathological and molecular data led to a delay in interception of this entity. Histopathology findings were suggestive of spindle-cell neoplasm. Contrastingly, next-generation sequencing (NGS) and immunohistochemistry (IHC) yielded a molecular diagnosis of PMBCL. IHC staining revealed that the atypical cells were positive for CD20, PAX5, CD79a, CD30, CD23, MUM1, and weakly positive for MAL (myelin and lymphocyte) protein. NGS showed increased expression of TNFRSF8 and CD274 genes, which encode CD30 and PDL1 proteins, respectively. The patient was successfully treated with the R-Hyper-CVAD protocol without consolidative radiotherapy.</p><p><strong>Conclusion: </strong>Diagnosing PMBCL can be challenging because it lacks pathognomonic features and shares characteristics with other lymphomas. Molecular testing is of paramount importance in this context owing to its distinctive immunophenotype.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"711-719"},"PeriodicalIF":0.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Attenuated\" Pulmonary Tumor Thrombotic Microangiopathy on Anti-Vascular Endothelial Growth Factor Treatment: A Case Report.","authors":"Haruka Ozaki, Takeshi Yamaguchi, Rika Kizawa, Yuko Tanabe, Koichi Suyama, Yuji Miura","doi":"10.1159/000543930","DOIUrl":"10.1159/000543930","url":null,"abstract":"<p><strong>Introduction: </strong>Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy (PTTM) is challenging because of rapidly worsening respiratory failure. Vascular endothelial growth factor (VEGF) is involved in PTTM pathogenesis; however, the clinical picture of PTTM in patients with cancer receiving anti-VEGF treatment is unknown.</p><p><strong>Case presentation: </strong>A 40-year-old man with advanced gastric adenocarcinoma on paclitaxel plus ramucirumab developed a dry cough and, after 2 months of a stable period, dyspnea on exertion. Chest computed tomography (CT) showed bilateral diffuse patchy ground-glass opacities (GGOs). Transbronchial biopsy revealed alveolar hemorrhage and small pulmonary arteries occluded with fibrocellular intimal proliferation, but no tumor cells. Suspecting chemotherapy-induced lung injury, we discontinued the chemotherapy and monitored him carefully without treatment. However, his dyspnea worsened, and follow-up chest CT showed worsening GGOs and right atrial and pulmonary arterial dilatation. Ultrasound cardiography indicated reduced right ventricular function. Lung perfusion scintigraphy confirmed numerous bilateral defects. Right heart catheterization revealed pulmonary hypertension, but no tumor cells on pulmonary wedge aspiration cytology. We clinically diagnosed the patient with PTTM. Three weeks after his initial visit for dyspnea, he was started on nivolumab. One week after treatment, he required home oxygen therapy at 1 L/min on exertion. After two doses of nivolumab, he no longer had dyspnea and discontinued oxygen therapy. Follow-up ultrasound cardiography showed normal pulmonary arterial pressure, and almost all GGOs on chest CT were resolved.</p><p><strong>Conclusion: </strong>VEGF inhibitors may attenuate PTTM symptoms. Even with mild respiratory symptoms, oncologists should consider PTTM in patients with cancer on VEGF inhibitors.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"659-666"},"PeriodicalIF":0.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spinal Metastases from Gastrointestinal Stromal Tumor: A Case Report.","authors":"Pashayar P Lookian, Luke J Weisbrod, Jordan M Rasmussen, Landon D Ehlers, Jie Chen, Tyler R Teichmeier, Miki Katzir","doi":"10.1159/000543568","DOIUrl":"10.1159/000543568","url":null,"abstract":"<p><strong>Introduction: </strong>Gastrointestinal stromal tumors (GISTs) arise from the interstitial cells of Cajal and are the most common form of gastrointestinal (GI) mesenchymal tumors. Bony metastasis is rare, with the spine being the most common location of osseous metastasis.</p><p><strong>Case presentation: </strong>A 56-year-old female with presentation of acute on chronic mechanical low back pain was found to have multiple lytic lesions throughout the thoracolumbar spine arising from GIST metastases. Magnetic resonance imaging of the thoracic spine revealed a dorsal epidural enhancing mass spanning the T6-T8 levels with associated spinal cord compression and spinal cord signal change. The patient underwent urgent surgical decompression and resection of epidural tumor through T5-T8 decompressive laminectomy. Postoperatively, the patient initially did well with improvement in bilateral lower extremity sensation and bladder function. The patient passed away while at home due to undetermined causes 6 weeks postoperatively.</p><p><strong>Conclusion: </strong>Here we present the case of a patient with metastatic GIST to the thoracic spine presenting with acute spinal cord compression treated with surgical resection, in addition to reviewing the literature of previous patients with metastatic GIST to the spine. We recommend that patients undergo surgical resection with adjuvant tyrosine kinase inhibitor therapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"675-681"},"PeriodicalIF":0.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}